Peptides for sleep: DSIP, Epitalon and the growth axis

Sleep is the most common reason people give for trying a peptide that is not a GLP-1. It is also an area where the gap between what is claimed and what has been tested is especially wide. Here is the evidence, graded honestly, for the two compounds most often named and for the biology that gets cited alongside them.

How we grade the evidence here

DSIP: the sleep peptide that was tested

Delta sleep-inducing peptide is a nine-amino-acid peptide isolated in the 1970s from rabbits, named for the deep, slow "delta" waves it appeared to produce. Unusually for this category, it was taken into human trials, mostly in the 1980s, mostly by intravenous infusion.

The early positive reports came largely from one investigator. The later, independent trials did not reproduce a useful effect, and research interest faded. No modern trial has revisited it. In July 2026, the FDA's compounding advisory committee voted 7 to 6, with one abstention, not to recommend emideltide for the 503A bulks list, the only one of the seven peptides it reviewed that week to be turned down. The FDA has said it has not identified safety information for the proposed route. See DSIP.

Epitalon: a sleep reputation without sleep trials

Epitalon (also spelled Epithalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, modelled on Epithalamin, an extract of bovine pineal gland developed in Russia. Most research on both comes from the St Petersburg group of Vladimir Khavinson. A 2025 review in the International Journal of Molecular Sciences describes a large body of cell, animal and computer-model work suggesting effects on melatonin synthesis, antioxidant enzymes and telomerase, and notes that whether these are its actual mechanisms remains uncertain.

The sleep connection rests on the pineal gland and melatonin. In a 2004 study, elderly people given a course of Epithalamin, the extract rather than the synthetic peptide, showed higher night-time melatonin if their baseline was low and slightly lower if it was normal. That is a melatonin measurement, not a sleep measurement. We could not find a placebo-controlled trial of Epitalon with sleep as the outcome. The PCAC recommended it for the bulks list in July 2026 by a narrow margin, on the question of pharmacy supply rather than on evidence of benefit. See Epitalon.

The growth axis: where the real biology is

There is genuine, well-replicated sleep science behind the idea that peptides and sleep are linked. In young men, the largest daily pulse of GH from the pituitary comes shortly after sleep onset, during the first period of deep slow-wave sleep. The hypothalamic signal that triggers that pulse, GHRH, also promotes slow-wave sleep. Studies from the Max Planck Institute of Psychiatry, in which volunteers were given GHRH in the sleep lab, showed more slow-wave sleep, while CRH, the stress-axis signal, had the opposite effect. Their reviews argue that the balance between the two shifts towards CRH with age and depression, which may help explain shallower sleep in both. Ghrelin and related GH-releasing peptides also promoted sleep in this work. Later studies found that GHRH's effects were different in women.

That is the scientific root of the claim that GH-axis peptides help sleep. The leap is from "the natural signal promotes deep sleep in a lab study" to "an injected analogue improves my sleep." Sermorelin, tesamorelin, CJC-1295 and ipamorelin act on this axis, but none has been tested in a trial with poor sleep as the condition being treated. Tesamorelin's FDA approval is for abdominal fat in people with HIV, not sleep. MK-677, often discussed in the same breath, is not a peptide at all; it is a small molecule. See sermorelin, tesamorelin, ipamorelin and MK-677.

What does have evidence for sleep

For chronic insomnia, the American College of Physicians recommends cognitive behavioural therapy for insomnia (CBT-I) as the first treatment for adults, ahead of sleeping pills. For sleep apnoea, tirzepatide now has an FDA indication in adults with obesity; see the sleep apnoea research page. Consistent wake times, light in the morning, less alcohol, and treating pain or reflux that wakes you are unglamorous and better supported than anything on this page. A clinician can also check for the causes a peptide would never touch: apnoea, restless legs, thyroid problems, depression.

If you are measuring it

Sleep is noisy night to night, which makes it easy to see an effect that is not there. Two weeks of baseline before any change, the same bedtime, and a wearable or diary that records the same things every night make the difference between a trend and a story. Peptide AI pulls sleep from your watch through wearable integrations and puts it on the same timeline as the dose log; the peptides for sleep page lists every compound in the library that is studied for it.